Alkylating Derivatives of Vitamin D Hormone for Prostate Cancer
Abstract
The two most significant achievements in this reporting period are : launching of studies to evaluate the molecular mechanism/s of action of . 1,25-dihydroxyvitamin D3-3-bromoacetate (1,25(OH)2D3-3-BE), and development of an androgen-sensitive mouse model of human prostate cancer. In addition we have screened several cancer cell lines to determine potential efficacy of 1,25(OH)2D3-3-BE in cancers, in addition to prostate cancer.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2008
- Accession Number
- ADA506555
Entities
People
- Rahul Ray
Organizations
- Boston University